[go: up one dir, main page]

WO1996021014A3 - Production and administration of high titer recombinant retroviruses - Google Patents

Production and administration of high titer recombinant retroviruses Download PDF

Info

Publication number
WO1996021014A3
WO1996021014A3 PCT/US1995/016852 US9516852W WO9621014A3 WO 1996021014 A3 WO1996021014 A3 WO 1996021014A3 US 9516852 W US9516852 W US 9516852W WO 9621014 A3 WO9621014 A3 WO 9621014A3
Authority
WO
WIPO (PCT)
Prior art keywords
administration
production
high titer
recombinant retroviruses
protein
Prior art date
Application number
PCT/US1995/016852
Other languages
French (fr)
Other versions
WO1996021014A2 (en
Inventor
Douglas J Jolly
Jack R Barber
Stephen M W Chang
James G Respess
John R Allen
Mordechai Bodner
Kimberly Chong
La Vega Dan De Jr
Nicholas J Depolo
David Chi-Tang Hsu
Carlos E Ibanez
Denice M Mittelstaedt
Charles E Prussak
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to EP95944227A priority Critical patent/EP0796331A2/en
Priority to AU46080/96A priority patent/AU4608096A/en
Publication of WO1996021014A2 publication Critical patent/WO1996021014A2/en
Publication of WO1996021014A3 publication Critical patent/WO1996021014A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid of cells of a human, comprising the step of administering human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 105 cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid of cells of the human.
PCT/US1995/016852 1994-12-30 1995-12-22 Production and administration of high titer recombinant retroviruses WO1996021014A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95944227A EP0796331A2 (en) 1994-12-30 1995-12-22 Production and administration of high titer recombinant retroviruses
AU46080/96A AU4608096A (en) 1994-12-30 1995-12-22 Production and administration of high titer recombinant retroviruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36707194A 1994-12-30 1994-12-30
US08/367,071 1994-12-30

Publications (2)

Publication Number Publication Date
WO1996021014A2 WO1996021014A2 (en) 1996-07-11
WO1996021014A3 true WO1996021014A3 (en) 1996-09-26

Family

ID=23445824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016852 WO1996021014A2 (en) 1994-12-30 1995-12-22 Production and administration of high titer recombinant retroviruses

Country Status (3)

Country Link
EP (1) EP0796331A2 (en)
AU (1) AU4608096A (en)
WO (1) WO1996021014A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1998000541A2 (en) * 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
AU8777898A (en) * 1997-08-11 1999-03-01 Chiron Corporation Methods for genetically modifying t cells
EP1009444A2 (en) * 1997-09-02 2000-06-21 Chiron Corporation Compositions and methods for treating arthritis utilizing gene therapy
JP2003286199A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Drug for treating liver disease using hollow protein nanoparticles
JP2003286198A (en) * 2002-03-29 2003-10-07 Japan Science & Technology Corp Therapeutic agent using protein hollow nanoparticles that display growth factors etc.
AU2003228751A1 (en) 2002-05-01 2003-11-17 Cell Genesys, Inc. Lentiviral vector particles resistant to complement inactivation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (en) * 1993-06-04 1994-12-22 The Regents Of The University Of California Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (en) * 1993-06-04 1994-12-22 The Regents Of The University Of California Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. JOLLY: "Viral vector systems for gene therapy", CANCER GENE THERAPY, vol. 1, no. 1, 1994, pages 51 - 64, XP002008051 *
D. MARKOWITZ ET AL.: "Retroviral gene transfer using safe and efficient packaging cell line", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 612, 1990, pages 407- - 414, XP002008048 *
D.M. BODINE ET AL.: "Development of a high titer retrovirus producer cell line and strategies for retrovirus-mediated gene transfer into rhesus monkey hematopoietic stem cells", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 612, 1990, pages 415 - 426, XP002008049 *
D.M. BODINE ET AL.: "Development of a high titer retrovirus producer cell line capable of gne transfer in rhesus monkey hematopoietic stem cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 87, 1990, pages 3738 - 3742, XP002008050 *
Y.-F. DAI ET AL.: "High efficient transfer and expression of human clotting factor IX cDNA in cultured human primary skin fibroblasts from hemophilia B patient by retroviral vectors", SCIENCE IN CHINA (SERIE B), vol. 35, no. 2, 1992, pages 183 - 193, XP002008052 *

Also Published As

Publication number Publication date
WO1996021014A2 (en) 1996-07-11
AU4608096A (en) 1996-07-24
EP0796331A2 (en) 1997-09-24

Similar Documents

Publication Publication Date Title
WO1998000541A3 (en) Methods for administration of recombinant gene delivery vehicles for treatment of human disease
EP0853121A3 (en) Human DNase
WO2002057435A3 (en) Bifunctional fusion proteins with glucocerebrosidase activity
AU661901B2 (en) Protein C derivatives
CA2066204A1 (en) Cystic fibrosis gene
AU4403689A (en) Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
ES2143641T3 (en) SURFACE EXPRESSION OF AN ENZYME IN GENE THERAPY BASED ON DRUGS.
EP0233013A3 (en) Modified enzyme
AU1951195A (en) Combinations of thrombolytically active proteins and anticoagulants, and uses thereof
EP0147146A3 (en) Enhancement of transdermal drug delivery
WO1996021014A3 (en) Production and administration of high titer recombinant retroviruses
EP0744408A3 (en) Rhesus ob protein and DNA
AU2157888A (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
CA2154080A1 (en) Novel anticoagulant cofactor activity
MY103362A (en) Production of proteins in active forms
AU3927189A (en) N-2,3-butadienyl tri- and tetraaminoalkane derivatives
WO1997026867A3 (en) Solid instant-release forms of administration and process for producing the same
CA2175061A1 (en) Muteins of Beta-Galactosidase Fragments Having Increased Activity
ATE187890T1 (en) LIGAND DIRECTED ENZYME PRODRUG THERAPY
WO1997002002A3 (en) Use of polyolpoly-12-hydroxystearates
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
AU3817495A (en) Use of erythropoietin in the treatment of rheumatoid arthritis
WO1998024482A3 (en) Use of endothelin conjugates in therapy, new endothelin conjugates, substances containing them, and processes for producing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1995944227

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995944227

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 1039

Date of ref document: 19971230

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995944227

Country of ref document: EP